People

<p>The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an &#8220;on-the-ground&#8221;, local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors.</p>


Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.”

Transforming Life Sciences Innovation By Creating And Investing In Global Companies

Catalys Pacific

Home

Developing Innovative Treatments for LINE-1 associated Neurodegenerative Disease

Transposon - Catalys Pacific

Transposon

IPO Archives - Catalys Pacific

Dr. Tachi Yamada

Chairman and Co-founder of Phathom Pharmaceuticals

<p>Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.</p>


Going Beyond to Advance Treatments for Patients with Acid-Related Disorders

Home

Creations

Transposon

Phathom Pharmaceuticals